DiazGranados Nancy, Zarate Carlos A
Mood and Anxiety Disorders Program, National Institute of Mental Health, National Institutes of Health, and Department of Health and Human Services, 10 Center Drive, CRC, Unit 7 Southeast, Room 7-3445, Bethesda, MD 20892, USA.
Curr Psychiatry Rep. 2008 Dec;10(6):510-9. doi: 10.1007/s11920-008-0081-7.
In this article, we review preclinical studies investigating the role of protein kinase C (PKC) as it pertains to mania and effective antimanic agents. We then discuss clinical studies conducted with tamoxifen, a relatively selective PKC inhibitor, in acute bipolar mania. We conclude that PKC is an important target-arguably the first mechanistically distinct drug target for bipolar disorder. PKC holds considerable promise as a novel target for developing a new line of treatments for bipolar disorder.
在本文中，我们回顾了关于蛋白激酶C（PKC）在躁狂症及有效抗躁狂药物中作用的临床前研究。然后我们讨论了用他莫昔芬（一种相对选择性的PKC抑制剂）治疗急性双相躁狂症的临床研究。我们得出结论，PKC是一个重要靶点——可以说是双相情感障碍第一个在机制上有别于其他的药物靶点。PKC作为开发双相情感障碍新治疗方法的新靶点具有很大的前景。
